Polypeptides modulating SIGLEC dependent immune responses

US11013789B2 · kind B2 · utility

Assignee

• OCTAPHARMA AG · CH

Inventors

• Christoph Kannicht · Berlin, DE
• Stefan Winge · Kramfors, SE
• Guido Kohla · Berlin, DE
• Barbara Solecka-Witulska · Berlin, DE

Key dates

• Filing date: May 22, 2017
• Grant date: May 25, 2021
• Expiry date: May 22, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/35
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to a glycosylated polypeptide comprising an amino acid sequence being identical or homologous to at least a fragment of a mammalian, preferably a human protein, wherein said glycosylated polypeptide contains one or more sialylated O-glycans and wherein the glycosylated polypeptide shows an increased binding affinity to one or more SIGLECs, selected from SIG-5, SIG-7, SIG-8, and SIG-9 compared to the mammalian protein or fragment thereof. The invention further relates to composition comprising a first and a second polypeptide, wherein the first polypeptide is a glycosylated polypeptide containing one or more sialylated O-glycans and the second polypeptide contains an amino acid sequence homologous or identical to a second mammalian, in particular human protein, wherein compared to the second polypeptide the composition has an increased binding affinity to a SIGLEC selected from to one or more SIGLECs, selected from SIG-5, SIG-7, SIG-8, and SIG-9.